2021 CMSC Annual Meeting

Tag: PhD1 and Ralf Gold

Poster-Disease-modifying Therapy

Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties

Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...

Read More